US-based bioanalytical contract research organization (CRO) Resolian has announced the acquisition of China-based CRO Denali Medpharma. While the financial details of the deal remain undisclosed, this strategic move significantly expands Resolian’s bioanalysis laboratory capabilities to China, complementing its existing operations in the US, UK, and Australia. This expansion allows Resolian’s clients to conduct therapeutic trials across various global destinations without the need to change CROs.
Expanding Global Laboratory Capabilities
The acquisition of Denali Medpharma enhances Resolian’s global footprint, providing clients with a seamless option to extend their therapeutic trials to China. This move is particularly beneficial for clients looking to diversify their clinical trial locations while maintaining consistency in CRO services.
Denali Medpharma’s Expertise and Services
Denali Medpharma, established by US-trained scientists, possesses specific expertise in a range of bioanalytical areas. The company specializes in oligonucleotides, mRNA, liposomal drugs, ultra-sensitive assays for inhalation drugs, and biomarker assays, among other services. These capabilities are particularly valuable in the development of novel therapeutics and the advancement of personalized medicine.-Fineline Info & Tech
